Werewolf Therapeutics Inc. (HOWL)
$0.95
$0.00
(0.35%)
As on 04-Sep-2026 13:35EDT
Market cap
$46 Mln
Revenue (TTM)
$21 Mln
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
48,599,066
5 Years Aggregate
CFO
$-144.25 Mln
EBITDA
$-175.36 Mln
Net Profit
$-164.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Werewolf Therapeutics (HOWL)
| 49.5 | 157.6 | 124.2 | -30.9 | -28.7 | -44.4 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Werewolf Therapeutics (HOWL)
| -57.2 | -61.4 | 88.3 | -82.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Werewolf Therapeutics (HOWL)
|
0.9 | 45.8 | 21.0 | -34.6 | -122.2 | -168.4 | -- | 2.9 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Werewolf Therapeutics (HOWL)
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally... activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. Read more
-
Founder, CEO, President, Secretary & Director
Dr. Daniel J. Hicklin Ph.D.
-
Founder, CEO, President, Secretary & Director
Dr. Daniel J. Hicklin Ph.D.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Werewolf Therapeutics (HOWL)
What is the current share price of Werewolf Therapeutics Inc (HOWL) Today?
The share price of Werewolf Therapeutics Inc (HOWL) is $0.95 (NASDAQ) as of 04-Sep-2026 13:35 EDT. Werewolf Therapeutics Inc (HOWL) has given a return of -28.67% in the last 3 years.
What is the current PB & PE ratio of Werewolf Therapeutics Inc (HOWL)?
Since, TTM earnings of Werewolf Therapeutics Inc (HOWL) is negative, P/E ratio is not available.
The P/B ratio of Werewolf Therapeutics Inc (HOWL) is 2.89 times as on 28-Aug-2026, a 44 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.49 |
1.20 |
2024 |
-0.93 |
0.90 |
2023 |
-3.78 |
1.27 |
2022 |
-1.22 |
0.52 |
2021 |
-6.53 |
2.13 |
What is the 52 Week High and Low of Werewolf Therapeutics Inc (HOWL)?
The 52-week high and low of Werewolf Therapeutics Inc (HOWL) are Rs 2.38 and Rs 0.27 as of 05-Sep-2026.
What is the market cap of Werewolf Therapeutics Inc (HOWL)?
Werewolf Therapeutics Inc (HOWL) has a market capitalisation of $ 46 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Werewolf Therapeutics Inc (HOWL)?
Before investing in Werewolf Therapeutics Inc (HOWL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.